Minimally invasive pancreaticoduodenectomy for periampullary disease: a comprehensive review of literature and meta-analysis of outcomes compared with open surgery

Table 4 Summary of Recurrence and Long-term Survivals

Author	Group	Malignant case	Follow-up (month)	Recurrence	Survival (time: month; rate: %)
Zureikat [31]	MIPD	12	9.5(4–21)	1	NR
Croome [55]	MIPD	108	16.5	44	MOS: 25.3 m
Croome [55]	OPD	214	15.1	113	MOS: 21.8 m
Hakeem [57]	MIPD	12	46.8(13.0–73.7)	2	1, 3, 5y–DFS: 100; 92, 83, 5y–OS: 100, 83, 83
Hakeem [57]	OPD	12	56.0(1.0–97.4)	2	1, 3, 5y–DFS: 100; 92, 75, 5y–OS: 75, 58, 50
Song [83]	MIPD	11	NR	NR	5y–OS: 53.6
Song [83]	OPD	222	NR	NR	5y–OS: 28.8
Chen [68]	MIPD	19	22 ± 10	NR	MDFS: 14.0 m; MOS: 23.0 m
Chen [68]	OPD	39	21 ± 8	NR	MDFS: 13.0 m; MOS: 22.0 m
Delitto [92]	MIPD	52	NR	NR	MOS: 27.9 m; MOS: 20.7 m*
Delitto [92]	OPD	50	NR	NR	MOS: 23.5 m; MOS: 21.1 m*
Palanivelu [15]	MIPD	49	36.5	NR	MOS: 49 m; 5y–OS: 30.4
Pugliese [16]	MIPD	11	32(12–45)	7	MDFS: 11 m; MOS: 18 m
Senthilnathan [80]	MIPD	130	24	NR	MOS: 33 m; 5y–OS:29.4
Wang [86]	MIPD	16	18(8–48)	10	MDFS: m16; MOS: 19 m
Coratti [90]	MIPD	41	15.8(2–47)	12	MOS: 40 m; 1, 2, 3y–OS: 81, 69, 55
Kantor [96]	MIPD	828	18	NR	MOS: 20.7 m
Kantor [96]	OPD	7385	18	NR	MOS: 20.9 m
Stauffer [107]	MIPD	58	19.6 ± 17.4	NR	MOS: 18.5 m; 1, 2, 3, 4, 5y–OS: 66.5, 43.3, 43.3, 38.5, 32.1
Stauffer [107]	OPD	193	24.5 ± 27.4	NR	MOS: 20.3 m; 1, 2, 3, 4, 5y–OS: 67.5, 40.2, 24.3, 17.1, 15.3

Follow-up time were shown as median (range) or median only; DFS: disease-free survival rate; OS: overall survival rate; MDFS: median disease-free survival time; MOS: median overall survival time; y: year; *special for PDAC; NR: not report

ISSN: 1471-230X